Abbott Laboratories $ABT Stake Lifted by Mitsubishi UFJ Trust & Banking Corp

Key Points

• Mitsubishi UFJ Trust & Banking Corp increased its stake in Abbott Laboratories by 1.3% to 1,077,751 shares (about $135 million), while institutional investors now own roughly 75.18% of the company.
• Abbott beat quarterly expectations, reporting $1.15 EPS vs. $1.14 expected and revenue of $11.16 billion (up 7.8% YoY), and set FY2026 guidance of $5.380–$5.580 EPS with Q2 guidance of $1.250–$1.310.
• The company declared a quarterly dividend of $0.63 per share (annualized $2.52, ~2.7% yield), and the stock carries a consensus rating of "Moderate Buy" with an average price target of $119.43.

Mitsubishi UFJ Trust & Banking Corp boosted its position in Abbott Laboratories (NYSE:ABT - Free Report) by 1.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,077,751 shares of the healthcare product maker's stock after purchasing an additional 14,224 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.06% of Abbott Laboratories worth $135,031,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Global Financial Private Client LLC boosted its stake in Abbott Laboratories by 3.3% during the third quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker's stock valued at $331,000 after buying an additional 79 shares in the last quarter. Citizens & Northern Corp lifted its holdings in Abbott Laboratories by 0.4% in the 3rd quarter. Citizens & Northern Corp now owns 21,875 shares of the healthcare product maker's stock valued at $2,930,000 after acquiring an additional 79 shares during the last quarter. American National Bank of Texas boosted its position in shares of Abbott Laboratories by 2.4% during the 4th quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker's stock valued at $427,000 after purchasing an additional 79 shares in the last quarter. Nia Impact Advisors LLC boosted its position in shares of Abbott Laboratories by 2.2% during the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker's stock valued at $504,000 after purchasing an additional 79 shares in the last quarter. Finally, Nova R Wealth Inc. grew its stake in shares of Abbott Laboratories by 3.0% in the 3rd quarter. Nova R Wealth Inc. now owns 2,802 shares of the healthcare product maker's stock worth $375,000 after purchasing an additional 81 shares during the last quarter. Institutional investors own 75.18% of the company's stock.

Abbott Laboratories Stock Performance

ABT stock opened at $92.85 on Tuesday. The firm has a 50 day simple moving average of $105.56 and a 200 day simple moving average of $116.83. Abbott Laboratories has a 52 week low of $90.72 and a 52 week high of $139.06. The stock has a market cap of $161.71 billion, a P/E ratio of 26.01, a P/E/G ratio of 1.52 and a beta of 0.79. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.71%. The business had revenue of $11.16 billion for the quarter, compared to analysts' expectations of $10.99 billion. During the same period in the previous year, the company posted $1.09 EPS. Abbott Laboratories's revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Research analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.7%. Abbott Laboratories's dividend payout ratio (DPR) is 70.59%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on ABT shares. Sanford C. Bernstein cut their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an "outperform" rating for the company in a research note on Friday, April 17th. Mizuho dropped their price target on Abbott Laboratories from $125.00 to $115.00 and set a "neutral" rating on the stock in a report on Friday, April 17th. Freedom Capital upgraded Abbott Laboratories from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 29th. Stifel Nicolaus decreased their target price on Abbott Laboratories from $145.00 to $120.00 and set a "buy" rating on the stock in a report on Friday, April 17th. Finally, Weiss Ratings lowered Abbott Laboratories from a "hold (c)" rating to a "hold (c-)" rating in a research report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $119.43.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 585 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $67,614.30. Following the completion of the sale, the vice president directly owned 24,628 shares in the company, valued at $2,846,504.24. The trade was a 2.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Eric Shroff sold 709 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the transaction, the senior vice president owned 39,164 shares in the company, valued at approximately $4,526,575.12. This trade represents a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 3,055 shares of company stock worth $353,097 over the last quarter. Insiders own 0.46% of the company's stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.